Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CETP | P11597 | 1/20 | 0.50 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27879510 | 0.98 | KDM4E (0.54) | KDM4EALDH1A1TDP1TSHRHSD17B10 | |
| SCHEMBL21770981 | 0.98 | KDM4E (0.54) | KDM4EALDH1A1TDP1TSHRHSD17B10 | |
| SCHEMBL26218121 | 0.94 | TAAR1 (0.50) | KDM4EALDH1A1TDP1TSHRHSD17B10 | |
| SCHEMBL25381878 | 0.91 | FDFT1 (0.57) | KDM4EALDH1A1TDP1TSHRHSD17B10 | |
| SCHEMBL6795855 | 0.89 | LTA4H (0.55) | KDM4EALDH1A1TDP1TSHRHSD17B10 | |
| SCHEMBL14127822 | 0.87 | FFAR1 (0.52) | KDM4EALDH1A1TDP1TSHRHSD17B10 | |
| SCHEMBL10106193 | 0.87 | PPARA (0.60) | CETPFDFT1LTA4H | |
| SCHEMBL25382577 | 0.86 | FDFT1 (0.49) | KDM4EALDH1A1TDP1TSHRHSD17B10 | |
| SCHEMBL23085167 | 0.86 | PPARA (0.62) | CETPLTA4H | |
| SCHEMBL29959530 | 0.86 | PPARA (0.62) | CETPLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4288387-A | REACTION OF A HALOGENOPENTENE OR HEXENE WITH A DIAZOACETIC ESTER IN THE PRESENCE OF CATALYST WHICH IS METALLIC COPPER, A COPPER SALT, A RHODIUM SALT, OR A TRANSITION METAL COMPLEX OF A CHIRAL SCHIFF BASE | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-09-08 | — | — | US | claimed |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11008596-B2 | Cytochrome P450 BM3 enzyme variants for preparation of cyclopropanes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20190211367-A1 | VIVO AND IN VITRO OLEFIN CYCLOPROPANATION CATALYZED BY HEME ENZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-07-11 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-9518000-B2 | Bicyclo [2.2.1] acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160113954-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | REDHILL BIOPHARMA LTD. (IL) | 2016-04-28 | — | — | US | disclosed |
| US-20160016880-A1 | BICYCLO [2.2.1] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| WO-2015179559-A2 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-9040715-B2 | 1,2-benzisothiazolinone and isoindolinone derivatives | GEORGETOWN UNIVERSITY (US) | 2015-05-26 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20090118160-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW THOMAS | 2009-05-07 | — | — | US | disclosed |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7453002-B2 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-7312200-B2 | 9-ketospinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2007-12-25 | — | — | US | disclosed |
| US-7312200-B2 | 9-ketospinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2007-12-25 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | disclosed |
| EP-0240121-A2 | Diphenyl ether derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-10-07 | — | — | EP | disclosed |
| EP-0064394-A1 | Manufacture of alpha-arylalkanoic acids and precursors | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1982-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118160-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | KDM4E 3718/4885ALDH1A1 557/4885TDP1 2568/4885 |
| US-20160113954-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | RNMT, EIF2AK2, POLRMT | KDM4E 2814/4885ALDH1A1 3057/4885TDP1 409/4885 |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, FAAH, FAAH2 | KDM4E 2168/4885ALDH1A1 1322/4885TDP1 4025/4885 |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | ADORA2A, ADORA2B, ADORA3 | KDM4E 4408/4885ALDH1A1 665/4885TDP1 3195/4885 |
| US-20160016880-A1 | BICYCLO [2.2.1] ACID GPR120 MODULATORS | GPR180, GPR88, GPBAR1 | KDM4E 4189/4885ALDH1A1 2096/4885TDP1 4809/4885 |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | PPARG, GPR119, PPARA | KDM4E 1746/4885ALDH1A1 845/4885TDP1 1787/4885 |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | KDM4E 988/4885ALDH1A1 4184/4885TDP1 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.